Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.

Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L.

Front Immunol. 2019 Jan 18;9:3175. doi: 10.3389/fimmu.2018.03175. eCollection 2018.

2.

Antigen-specific CD8 T cells in cell cycle circulate in the blood after vaccination.

Simonetti S, Natalini A, Folgori A, Capone S, Nicosia A, Santoni A, Di Rosa F.

Scand J Immunol. 2019 Feb;89(2):e12735. doi: 10.1111/sji.12735. Epub 2019 Jan 15.

PMID:
30488973
3.

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8+ T Cells by Persistent Viruses and Vaccines.

Gordon CL, Lee LN, Swadling L, Hutchings C, Zinser M, Highton AJ, Capone S, Folgori A, Barnes E, Klenerman P.

Cell Rep. 2018 Apr 17;23(3):768-782. doi: 10.1016/j.celrep.2018.03.074.

4.

Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy.

Spada E, Rezza G, Garbuglia AR, Lombardo FL, Zuccaro O, Menniti Ippolito F, Cupellaro E, Capone S, Capobianchi MR, Nicosia A, Cortese R, Folgori A, Mele A; Collaborative Study Group.

J Urban Health. 2018 Feb;95(1):99-110. doi: 10.1007/s11524-017-0207-5.

5.

Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.

Vitelli A, Folgori A, Scarselli E, Colloca S, Capone S, Nicosia A.

Expert Rev Vaccines. 2017 Dec;16(12):1241-1252. doi: 10.1080/14760584.2017.1394842. Epub 2017 Oct 30. Review.

PMID:
29047309
6.

Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.

Xu H, Andersson AM, Ragonnaud E, Boilesen D, Tolver A, Jensen BAH, Blanchard JL, Nicosia A, Folgori A, Colloca S, Cortese R, Thomsen AR, Christensen JP, Veazey RS, Holst PJ.

EBioMedicine. 2017 Apr;18:204-215. doi: 10.1016/j.ebiom.2017.03.003. Epub 2017 Mar 8.

7.

Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix.

Ragonnaud E, Andersson AC, Mariya S, Pedersen AG, Burk RD, Folgori A, Colloca S, Cortese R, Nicosia A, Pamungkas J, Iskandriati D, Holst PJ.

J Immunother. 2017 Feb/Mar;40(2):51-61. doi: 10.1097/CJI.0000000000000153.

PMID:
28166180
8.

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Andersson AC, Ragonnaud E, Seaton KE, Sawant S, Folgori A, Colloca S, Labranche C, Montefiori DC, Tomaras GD, Holst PJ.

Vaccine. 2016 Oct 17;34(44):5344-5351. doi: 10.1016/j.vaccine.2016.08.089. Epub 2016 Sep 12.

9.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E.

Vaccines (Basel). 2016 Aug 2;4(3). pii: E27. doi: 10.3390/vaccines4030027.

10.

Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.

Bolinger B, Sims S, Swadling L, O'Hara G, de Lara C, Baban D, Saghal N, Lee LN, Marchi E, Davis M, Newell E, Capone S, Folgori A, Barnes E, Klenerman P.

Cell Rep. 2015 Nov 24;13(8):1578-88. doi: 10.1016/j.celrep.2015.10.034. Epub 2015 Nov 12.

11.

Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.

Callendret B, Eccleston HB, Satterfield W, Capone S, Folgori A, Cortese R, Nicosia A, Walker CM.

Hepatology. 2016 May;63(5):1442-54. doi: 10.1002/hep.28309. Epub 2015 Dec 18.

12.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Hepatology. 2016 May;63(5):1455-70. doi: 10.1002/hep.28294. Epub 2016 Jan 22.

13.

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.

Taylor G, Thom M, Capone S, Pierantoni A, Guzman E, Herbert R, Scarselli E, Napolitano F, Giuliani A, Folgori A, Colloca S, Cortese R, Nicosia A, Vitelli A.

Sci Transl Med. 2015 Aug 12;7(300):300ra127. doi: 10.1126/scitranslmed.aac5757.

PMID:
26268314
14.

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ.

Sci Transl Med. 2015 Aug 12;7(300):300ra126. doi: 10.1126/scitranslmed.aac5745.

15.

CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.

Fergusson JR, Hühn MH, Swadling L, Walker LJ, Kurioka A, Llibre A, Bertoletti A, Holländer G, Newell EW, Davis MM, Sverremark-Ekström E, Powrie F, Capone S, Folgori A, Barnes E, Willberg CB, Ussher JE, Klenerman P.

Mucosal Immunol. 2016 Mar;9(2):401-13. doi: 10.1038/mi.2015.69. Epub 2015 Jul 29.

16.

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Pierantoni A, Esposito ML, Ammendola V, Napolitano F, Grazioli F, Abbate A, Del Sorbo M, Siani L, D'Alise AM, Taglioni A, Perretta G, Siccardi A, Soprana E, Panigada M, Thom M, Scarselli E, Folgori A, Colloca S, Taylor G, Cortese R, Nicosia A, Capone S, Vitelli A.

Mol Ther Methods Clin Dev. 2015 May 20;2:15018. doi: 10.1038/mtm.2015.18. eCollection 2015.

17.

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, Lynn GM, Darrah PA, Lindsay RW, Wang L, Cheng C, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gall JG, Roederer M, Aderem A, Seder RA.

J Clin Invest. 2015 Mar 2;125(3):1129-46. doi: 10.1172/JCI78280. Epub 2015 Feb 2.

18.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

19.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Sci Transl Med. 2014 Nov 5;6(261):261ra153. doi: 10.1126/scitranslmed.3009185.

20.

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.

Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, Klenerman P, Barnes E.

Eur J Immunol. 2015 Jan;45(1):309-16. doi: 10.1002/eji.201444686. Epub 2014 Oct 30.

21.

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ.

Nat Med. 2014 Oct;20(10):1126-9. doi: 10.1038/nm.3702. Epub 2014 Sep 7.

PMID:
25194571
22.

T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.

Callendret B, Eccleston HB, Hall S, Satterfield W, Capone S, Folgori A, Cortese R, Nicosia A, Walker CM.

Hepatology. 2014 Nov;60(5):1531-40. doi: 10.1002/hep.27278. Epub 2014 Sep 25.

23.

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.

Spencer AJ, Cottingham MG, Jenks JA, Longley RJ, Capone S, Colloca S, Folgori A, Cortese R, Nicosia A, Bregu M, Hill AV.

PLoS One. 2014 Jun 19;9(6):e100538. doi: 10.1371/journal.pone.0100538. eCollection 2014.

24.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

25.

Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.

Capone S, Naddeo M, D'Alise AM, Abbate A, Grazioli F, Del Gaudio A, Del Sorbo M, Esposito ML, Ammendola V, Perretta G, Taglioni A, Colloca S, Nicosia A, Cortese R, Folgori A.

Mol Ther. 2014 May;22(5):1039-47. doi: 10.1038/mt.2014.15. Epub 2014 Jan 30.

26.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

27.

Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection.

Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, Folgori A, Rehermann B.

Nat Med. 2013 Dec;19(12):1638-42. doi: 10.1038/nm.3408. Epub 2013 Nov 24.

28.

Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.

Spada E, Amoroso P, Taliani G, Zuccaro O, Chiriacò P, Maio P, Maio G, Esposito ML, Mariano C, Rinaldi R, Bellissima P, Tosti ME, Del Porto P, Francavilla R, Mellace V, Garbuglia AR, Folgori A, Mele A; Acute Hepatitis Italian Study Group.

Clin Infect Dis. 2013 Sep;57(6):803-11. doi: 10.1093/cid/cit402. Epub 2013 Jun 19.

29.

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C.

J Hepatol. 2013 Aug;59(2):221-8. doi: 10.1016/j.jhep.2013.04.007. Epub 2013 Apr 12.

PMID:
23587473
30.

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A.

Expert Rev Vaccines. 2013 Apr;12(4):379-93. doi: 10.1586/erv.13.15. Review.

PMID:
23560919
31.

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.

Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, Price DA, Gomez CE, Esteban M, Wyatt LS, Moss B, Morgan C, Roederer M, Bailer RT, Nabel GJ, Koup RA, Seder RA.

J Immunol. 2013 Mar 15;190(6):2720-35. doi: 10.4049/jimmunol.1202861. Epub 2013 Feb 6.

32.

IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection.

Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B.

Hepatology. 2012 Dec;56(6):2060-70. doi: 10.1002/hep.25897. Epub 2012 Nov 19.

33.

Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus.

Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B.

Gastroenterology. 2012 Oct;143(4):1048-60.e4. doi: 10.1053/j.gastro.2012.06.005. Epub 2012 Jun 13.

34.

Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection.

Abdelwahab SF, Zakaria Z, Sobhy M, Rewisha E, Mahmoud MA, Amer MA, Del Sorbo M, Capone S, Nicosia A, Folgori A, Hashem M, El-Kamary SS.

Clin Vaccine Immunol. 2012 May;19(5):780-6. doi: 10.1128/CVI.00050-12. Epub 2012 Mar 21.

35.

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.

Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Słowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A.

J Hepatol. 2012 Jul;57(1):17-23. doi: 10.1016/j.jhep.2012.02.018. Epub 2012 Mar 10.

PMID:
22414763
36.

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV.

J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.

37.

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O'Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A.

Sci Transl Med. 2012 Jan 4;4(115):115ra2. doi: 10.1126/scitranslmed.3002925.

38.

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P.

Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.

39.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

40.

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.

Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, Hill AV.

Vaccine. 2010 Dec 16;29(2):256-65. doi: 10.1016/j.vaccine.2010.10.041. Epub 2010 Oct 26.

PMID:
21029806
41.

Prime-boost vectored malaria vaccines: progress and prospects.

Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ.

Hum Vaccin. 2010 Jan;6(1):78-83. Epub 2010 Jan 18. Review.

42.

Impact of viral selected mutations on T cell mediated immunity in chronically evolving and self limiting acute HCV infection.

Guglietta S, Garbuglia AR, Salichos L, Ruggeri L, Folgori A, Perrone MP, Camperio C, Mellace V, Maio G, Maio P, Capobianchi MR, Spada E, Gargano N, Scottà C, Piccolella E, Del Porto P.

Virology. 2009 Apr 10;386(2):398-406. doi: 10.1016/j.virol.2009.01.020. Epub 2009 Feb 20.

43.

Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM.

J Virol. 2008 Nov;82(21):10896-905. doi: 10.1128/JVI.01179-08. Epub 2008 Aug 27.

44.

Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients.

Riva E, Maggi F, Abbruzzese F, Bellomi F, Giannelli G, Picardi A, Scagnolari C, Folgori A, Spada E, Piccolella E, Dianzani F, Antonelli G; Acute Hepatitis C Italian Study Group.

Med Microbiol Immunol. 2009 Feb;198(1):13-8. doi: 10.1007/s00430-008-0099-9. Epub 2008 Aug 12.

PMID:
18696111
45.

The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection.

Shin EC, Capone S, Cortese R, Colloca S, Nicosia A, Folgori A, Rehermann B.

J Virol. 2008 Oct;82(19):9782-8. doi: 10.1128/JVI.00475-08. Epub 2008 Jul 30.

46.

Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection.

Scottà C, Garbuglia AR, Ruggeri L, Spada E, Laurenti L, Perrone MP, Girelli G, Mele A, Capobianchi MR, Folgori A, Nicosia A, Del Porto P, Piccolella E; Acute Hepatitis C Italian Study Group.

J Hepatol. 2008 Feb;48(2):216-28. doi: 10.1016/j.jhep.2007.09.011. Epub 2007 Nov 20.

PMID:
18180071
47.

Identification of four novel MHC-C alleles in chimpanzees.

Caggiari L, Rehermann B, Folgori A, De Re V.

Tissue Antigens. 2007 Jul;70(1):78-9.

PMID:
17559591
48.

Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates.

Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J, Ruggeri L, Arcuri M, Cappelletti M, Meola A, Ercole BB, Tafi R, Santini C, Luzzago A, Fu TM, Colloca S, Ciliberto G, Cortese R, Nicosia A, Fattori E, Folgori A.

J Immunol. 2006 Nov 15;177(10):7462-71.

49.

Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years.

Persico M, Perrotta S, Persico E, Terracciano L, Folgori A, Ruggeri L, Nicosia A, Vecchione R, Mura VL, Masarone M, Torella R.

J Viral Hepat. 2006 May;13(5):290-6.

PMID:
16637858
50.

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.

Fattori E, Zampaglione I, Arcuri M, Meola A, Ercole BB, Cirillo A, Folgori A, Bett A, Cappelletti M, Sporeno E, Cortese R, Nicosia A, Colloca S.

Gene Ther. 2006 Jul;13(14):1088-96. Epub 2006 Mar 23.

PMID:
16554842

Supplemental Content

Loading ...
Support Center